Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
Status:
Recruiting
Trial end date:
2023-04-27
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of pralatrexate when given
together with pembrolizumab and how well they work in treating patients with peripheral
T-cell lymphomas that has come back after a period of improvement or has not responded to
treatment. Pralatrexate may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may
help the body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. Giving pembrolizumab and pralatrexate may work better in treating
patients with peripheral T-cell lymphomas.